HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maron, B. J. Articles by Aeppli, D. M. Search for Related Content PubMed Articles by Maron, B. J. Articles by Aeppli, D. M.

Clinical course of hypertrophiccardiomyopathy with survival to advanced age

Barry J. Maron, MD, FACC^*,*, Susan A. Casey, RN^*, Robert G. Hauser, MD, FACC^* and Dorothee M. Aeppli, PhD

^* Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA

View larger version (45K): [in a new window]   Figure 1 Distribution of ages (at last evaluation or death) in 312 patients with hypertrophic cardiomyopathy (HCM), showing those patients who survived, died of HCM-related causes, or died of causes unassociated with HCM.

View larger version (29K): [in a new window]   Figure 2 Presence of basal left ventricular outflow tract gradient (LVOT) (at or near the time of initial diagnostic evaluation) shown separately for subaortic gradients of 30 to 49 mm Hg and 50 mm Hg. Expressed as the proportion of patients in each age subgroup with outflow obstruction, and depicted with respect to age at last evaluation (or death).

View larger version (19K): [in a new window]   Figure 3 Actuarial curves showing survival probabilities with respect to all causes of death for the hypertrophic cardiomyopathy (HCM) study population from the time of initial diagnosis, compared to expected survival probabilities of an age- and gender-matched cohort from the U.S. general population (Gen. Pop.) (24).

View larger version (23K): [in a new window]   Figure 4 Actuarial curves showing survival probabilities with hypertrophic cardiomyopathy (HCM) with respect to all causes of death, from the time of initial diagnosis. Shown separately for patients with HCM diagnosis <50 years and 50 years, and compared to expected survival probabilities of an age and gender-matched cohort from the U.S. general population (Gen. Pop.) (24).